At the recent ASCO 2018 Gastrointestinal Cancer Symposium (GI18), Steven. D Leach MD (Dartmouth) gave an excellent Keynote Lecture on “Mapping the Immune Landscape in Pancreatic Cancer.”

Pancreatic cancer has very poor outcomes, with a one-year relative survival rate (across all stages of the disease of 20%) and five-survival rate of 7% according to the American Cancer Society.  In addition, stage IV exocrine pancreatic cancer has a 5 year survival of about 1%, which is utterly dismal to say the least.

When it comes to cancer immunotherapy, so far we’ve not seen the success in pancreatic cancer that we’ve seen in other tumours, there are no FDA approved cancer immunotherapies for this disease.

Which raises a critical question of what is happening in the immune landscape of pancreatic cancer patients, and how will cancer immunotherapy be effective?

In this post, we discuss some of the key points that Dr Leach made in excellent presentation and look at some new developments on the horizon in PDAC.

To learn more and get a heads up on our latest conference insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers